Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE? [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Keytruda, approved for several types of cancer, alone accounts for more than 50% of the company's pharmaceutical sales. The drug has played a key role in driving Merck's steady revenue growth over the past few years. Keytruda recorded sales of $23.3 billion in the first nine months of 2025, up 8% year over year. As Keytruda approaches its expected loss of exclusivity in 2028, Merck's expanding pipeline and newly launched products are expected to shape the company's future business layout. MRK's phase III pipeline has almost tripled since 2021, driven by in-house pipeline progress and the addition of new candidates through various mergers and acquisitions (M&A) deals. This has positioned the company to launch around 20 new vaccines and drugs over the next few years, with many having blockbuster potential, creating long-term value. These include Merck's new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension (PAH) drug, Winrevair. Merck is pin
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Morgan Stanley from $100.00 to $102.00. They now have an "equal weight" rating on the stock.MarketBeat
- Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIRâ„¢ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)Business Wire
- Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1 [Yahoo! Finance]Yahoo! Finance
- Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104 [Yahoo! Finance]Yahoo! Finance
- Merck (NYSE:MRK) Could Be A Buy For Its Upcoming Dividend [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 12/4/25 - Form 8-K
- 12/3/25 - Form 424B5
- 12/2/25 - Form FWP
- MRK's page on the SEC website